Home › Arrhythmia › NCT06100770

Aveir AR Coverage With Evidence Development (CED) Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Medicare beneficiaries implanted with an Aveir AR leadless pacemaker on or after the study start date (i.e., the date of Aveir AR market approval) will be included in the study.

   OR
2. Medicare beneficiaries implanted with a full system (e.g. lead and generator) single chamber atrial transvenous pacemaker on or after the study start date

Exclusion Criteria:

* None

About the study

The purpose of this coverage with evidence development (CED) study is to evaluate complications and long-term health outcomes of the single-chamber Aveir Atrial Leadless Pacemaker device (aka Aveir™ AR LP system).

What is being tested

• Aveir AR Leadless Pacemaker (device)
• Single-chamber atrial transvenous pacemaker (device)

Sponsor: Abbott Medical Devices · Participants: 586 · Started: Jan 18, 2024

Contact the study team

• Nicole Harbert · Phone: 972-526-4841
• Stephanie Delgado · Phone: 818-493-3285

Official record on ClinicalTrials.gov — NCT06100770

Locations in the U.S.

Conditions

• Arrhythmia
• Bradycardia

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.